Evecxia Therapeutics Announces Data Presentations on Lead Candidate EVX-101 at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Evecxia Therapeutics Receives Notice Of Allowance For A U.S. Patent Covering Its Lead Drug Candidate EVX‑101
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
Evecxia Therapeutics Announces Leadership Transition to Support Next Phase of Development and Growth
Evecxia Therapeutics Announces Issuance of US Patent Covering EVX-101 for Depression and Other CNS Disorders
Evecxia Therapeutics Appoints Thomas Aasen to Board of Directors
Evecxia Provides Corporate Update: Completes Series A Financing, Achieves first-in-human dosing with EVX-101 and Announces collaboration with Tempus for data-driven Precision Medicine
Evecxia Inc. Appoints Jacob Jacobsen, PhD, as Chief Scientific Officer
Duke University publishes in Neuropsychopharmacology that slow-release delivery markedly enhances the therapeutic properties of oral 5-HTP
Columbia University publishes in Gastroenterology that 5-HTP slow-release treats constipation in an animal model
Evecxia licenses additional IP from NUS, NUH and NTU in Singapore
Evecxia licenses additional IP from Duke University
Jacobsen JPR, Oh A, Bangle R, et al. Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept. Neuropsychopharmacology. 2019;44(12):2082-2090.
This comprehensive study was designed to optimize translational fidelity, It reports that high-dose oral adjunctive 5-HTP slow-release in mice is safe and effective in amplifying brain serotonin neurotransmission beyond the SSRI effect, as assessed by behavioral, biochemical, and gene transcription measures.
Jacobsen JPR, Krystal AD, Krishnan KRR, et al. Adjunctive 5-hydroxytryptophan slow-release for treatment-resistant depression: clinical and preclinical rationale. Trends Pharmacol Sci. 2016;37(11):933-944.
This paper reviews the multipronged clinical data supporting that adjunctive 5-HTP SR could treat depression patients responding inadequately to first-line SSRI/SNRI antidepressants. That clinical data relates to earlier 5-HTP clinical research as well as clinical research with serotonergic antidepressants and compounds more broadly. Key supportive preclinical data is reviewed as well.
Jacobsen JP, Rudder ML, Roberts W, et al. SSRI augmentation by 5-hydroxytryptophan slow release: mouse pharmacodynamic proof of concept. Neuropsychopharmacology. 2016;41(9):2324-2334.
This study reports that 5-HTP slow-release synergizes with chronic SSRI in elevating extracellular serotonin in mice. It further demonstrates, assessing across a variety of physiological and behavioral measures, that slow-release delivery dramatically improves the safety and tolerability of 5-HTP administration.